AZN slides over 3% as Wainua Phase III clinical trial fails to meet efficacy goals

Traders Union
All News
Financial News
Astrazeneca slides 3.03% today on trial news

Highlights

AstraZeneca lost £23.3 billion in market value after its Phase III Wainua trial missed the primary endpoint in cardiomyopathy patients.
The failed trial prompted a securities disclosure investigation, but analyst sentiment toward AstraZeneca remained mostly unchanged.
Technically, AstraZeneca trades below key averages with most indicators signaling oversold conditions and a 71% likelihood for further downside toward GBX11,881 over the next week.

Disclosure scrutiny rises as market loss contrasts with steady analyst sentiment

On July 9, 2026, AstraZeneca reported that its Phase III CARDIO-TTRansform trial for Wainua (eplontersen), developed with Ionis Pharmaceuticals, did not achieve the primary efficacy endpoint in transthyretin-mediated amyloid cardiomyopathy patients. The outcome resulted in the loss of approximately £23.3 billion in market value at the day's low and led to a securities investigation into the company's disclosure practices. Analyst sentiment toward the company was reported as largely unchanged following the trial results.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca facing serious headwinds after failing the primary endpoint in its key heart drug trial. He notes the stock’s decisive drop and continued weakness below crucial moving averages, reflecting broad technical and fundamental strain. Kharitonov points to the £23.3 billion market value loss and a looming securities investigation as additional reasons for negative sentiment. He highlights that despite little change in analyst outlooks, indicators like ADX and RSI reinforce the bearish narrative. "The market’s reaction to the clinical failure and disclosure investigation shows there’s little near-term confidence in a turnaround for AstraZeneca," he states.

Viktoras Karapetjanc, expert at Traders Union, believes AstraZeneca’s structural growth story remains robust despite short-term volatility. He highlights the company’s stable analyst sentiment and positions the recent trial disappointment as a catalyst for market reset rather than a trend reversal. Karapetjanc is confident that strong fundamentals and institutional support will underpin a recovery path. He suggests the volatility band presents opportunity for active investors. "This event-driven pullback offers new entry points in a fundamentally sound megacap — I expect AstraZeneca to resume its uptrend in due time," he says.

Jainam Mehta, market strategist, sees AstraZeneca trapped between technical oversold readings and unresolved news risk from the trial miss. He observes that mixed momentum signals and the ongoing investigation may limit near-term upside, but deeply oversold levels could attract tactical buyers for range-bound trades. Mehta notes potential for contrarian entries if sentiment stabilizes, especially near GBX12,388. "If price stabilizes around support, a short-term bounce toward GBX13,080 is plausible for nimble traders," he says.

Mixed momentum signals as stock resists at key technical barriers

AstraZeneca is trading below its 20-day (GBX13,810), 50-day (GBX13,720), and 200-day (GBX13,778) moving averages, indicating persistent short-, medium-, and long-term pressure from sellers. The Ichimoku Kijun at GBX13,305 acts as nearby resistance, with the near-term ceiling and floor at GBX13,080 and GBX12,388, respectively. Momentum signals are mixed: the MACD gives a strong buy signal, yet the Average Directional Index (ADX) and Relative Strength Index (RSI) both indicate selling momentum and weakening strength. Stochastic RSI, CCI, and Bull/Bear Power (BBP) all point to oversold territory, with BBP showing sellers firmly in control. The Awesome Oscillator is neutral, signaling no clear supporting trend from the AO.

Previously, analysts noted that AstraZeneca's trial setback and the resulting negative sentiment were likely to weigh on shares while keeping a close focus on fundamental stability. The latest technical and momentum signals suggest persistent downside risk, making GBX11,881 a crucial level to watch for any additional weakness in the trading days ahead.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.